Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$126.16 USD

126.16
3,139,405

-2.48 (-1.93%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $125.50 -0.66 (-0.52%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 11% (224 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why

In the latest trading session, Novo Nordisk (NVO) closed at $126.16, marking a -1.93% move from the previous day.

Kinjel Shah headshot

4 Large Drug Stocks to Hold on to Amid Industry Challenges

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.

Kinjel Shah headshot

Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?

Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.

Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies

Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.

Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, Novo Nordisk (NVO) closed at $123.46, marking a -0.36% move from the previous day.

The Zacks Analyst Blog Highlights Microsoft, Novo Nordisk, United Parcel Service, Booking and Elevance Health

Microsoft, Novo Nordisk, United Parcel Service, Booking and Elevance Health are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Microsoft, Novo Nordisk & United Parcel

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Novo Nordisk A/S (NVO) and United Parcel Service, Inc. (UPS).

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: MediaAlpha, NVIDIA, Walmart in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Novo Nordisk (NVO) Gains As Market Dips: What You Should Know

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $124.93, denoting a +0.06% change from the preceding trading day.

Biophytis (BPTS) to Begin Phase II Obesity Study, Stock Up

Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.

Neena Mishra headshot

Healthcare ETFs for the Weight-Loss Drug Boom & Beyond

We discuss attractive investment opportunities within the healthcare industry.

Wall Street Analysts Think Novo Nordisk (NVO) Is a Good Investment: Is It?

The average brokerage recommendation (ABR) for Novo Nordisk (NVO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Here's Why Novo Nordisk (NVO) Fell More Than Broader Market

Novo Nordisk (NVO) closed at $127.55 in the latest trading session, marking a -0.66% move from the prior day.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: NVIDIA, Dell, Modine in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Why Novo Nordisk (NVO) is a Top Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

Andrew Rocco headshot

2 Top Biotech Buyout Candidates

The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities

Kinjel Shah headshot

Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs

While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.

Viking (VKTX) Up 17% on Encouraging Oral Obesity Drug Data

Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.

Novo Nordisk (NVO) to Buy Cardior to Boost Heart Disease Pipeline

Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals for 1.025 billion euros to establish a presence in cardiovascular disease.

Wall Street Awaits Consumer Confidence Data

Wall Street Awaits Consumer Confidence Data

Wall Street Set to Post Fifth Winning Month Amid Volatility

Wall Street is likely to record the fifth consecutive winning month despite volatility.

Why the Market Dipped But Novo Nordisk (NVO) Gained Today

Novo Nordisk (NVO) closed the most recent trading day at $129.05, moving +0.23% from the previous trading session.

Novo Nordisk (NVO) Gets Positive CHMP Opinion for Insulin Icodec

Novo Nordisk (NVO) receives a positive opinion from the CHMP for once-weekly basal insulin icodec for the treatment of diabetes in adults.

Zacks Investment Ideas feature highlights: Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics

Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics have been highlighted in this Investment Ideas article.